Strategy 9.5
Just refining my idea on the trial. With the breast cancer cardio protect anti cancer / FTO / CDx 3 in 1.
1. Trial must be structured from the outset with use of CDx.
2. Can run BC (inc mBC) Cardio protect and FTO trial in one.
3. Use genetic data for Pre marketing approval (PMA) for post approval 501(k).
4. Trial to be a satisfied randomised trial design, MAMS or FOCUS4 design to provide proof of concept with Dox + Zan.
5. Majority of sites in Australia R&D grant and less expensive.
6. Also given low patient population for mBC recruitment challenges so overseas trial EUR or US and apply overseas advance finding ruling to claim R&D for overseas costs.
7. Then payout COH early exit payment - due to transaction occurring before 8 July 2027 P3 first patient dosed deadline.
8. Retire!….
p.s. still having a think about AML and happy to be corrected by anyone on here : )
General Comments / Chat, page-9427
-
- There are more pages in this discussion • 1,802 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.59 |
Change
-0.015(0.93%) |
Mkt cap ! $273.4M |
Open | High | Low | Value | Volume |
$1.69 | $1.69 | $1.59 | $275.3K | 168.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 60 | $1.59 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.61 | 3160 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 60 | 1.590 |
1 | 10000 | 1.585 |
1 | 2500 | 1.580 |
1 | 5712 | 1.565 |
2 | 8233 | 1.560 |
Price($) | Vol. | No. |
---|---|---|
1.610 | 3160 | 1 |
1.615 | 2500 | 1 |
1.620 | 3588 | 1 |
1.650 | 5506 | 1 |
1.655 | 1069 | 1 |
Last trade - 10.40am 30/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online